Citron research is now long ValeantAccording to seeking alpha...
The hot place down under has officially frozen over. Noted bear Andrew Left of Citron Research fame says he is now
long Valeant Pharmaceuticals (
VRX +4.7%). He says he "wouldn't be surprised if there is a bounce" in the stock considering the prolonged downtrend. He also points out the importance of
Xifaxan (rifaximin), acquired in the Salix deal, which the company expects to be a key growth driver as it looks to lighten its debt load.